CN106883216A - 一种奥希替尼的制备方法 - Google Patents
一种奥希替尼的制备方法 Download PDFInfo
- Publication number
- CN106883216A CN106883216A CN201710220841.7A CN201710220841A CN106883216A CN 106883216 A CN106883216 A CN 106883216A CN 201710220841 A CN201710220841 A CN 201710220841A CN 106883216 A CN106883216 A CN 106883216A
- Authority
- CN
- China
- Prior art keywords
- preparation
- buddhist nun
- reaction
- wishes
- generation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 238000006243 chemical reaction Methods 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000002841 Lewis acid Substances 0.000 claims abstract description 6
- 150000007517 lewis acids Chemical class 0.000 claims abstract description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 238000005660 chlorination reaction Methods 0.000 claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 35
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 17
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical class C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 claims description 13
- GMWOSSBFNSZKAH-UHFFFAOYSA-N 1-fluoro-3-methoxy-2-nitrobenzene Chemical class COC1=CC=CC(F)=C1[N+]([O-])=O GMWOSSBFNSZKAH-UHFFFAOYSA-N 0.000 claims description 8
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 7
- 229910017604 nitric acid Inorganic materials 0.000 claims description 7
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 claims description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 claims description 4
- 229910021630 Antimony pentafluoride Inorganic materials 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 2
- VBVBHWZYQGJZLR-UHFFFAOYSA-I antimony pentafluoride Chemical compound F[Sb](F)(F)(F)F VBVBHWZYQGJZLR-UHFFFAOYSA-I 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000006396 nitration reaction Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims 2
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000000977 initiatory effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 238000011938 amidation process Methods 0.000 abstract description 2
- BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical class C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 abstract 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract 1
- BNUHAJGCKIQFGE-UHFFFAOYSA-N Nitroanisol Chemical compound COC1=CC=C([N+]([O-])=O)C=C1 BNUHAJGCKIQFGE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 238000003756 stirring Methods 0.000 description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 238000010792 warming Methods 0.000 description 7
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000004176 ammonification Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- -1 propylene Acyl chlorides Chemical class 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229950003988 decil Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- JSYBAZQQYCNZJE-UHFFFAOYSA-N benzene-1,2,4-triamine Chemical class NC1=CC=C(N)C(N)=C1 JSYBAZQQYCNZJE-UHFFFAOYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- UQXKXGWGFRWILX-UHFFFAOYSA-N ethylene glycol dinitrate Chemical compound O=N(=O)OCCON(=O)=O UQXKXGWGFRWILX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710220841.7A CN106883216B (zh) | 2017-04-06 | 2017-04-06 | 一种奥希替尼的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710220841.7A CN106883216B (zh) | 2017-04-06 | 2017-04-06 | 一种奥希替尼的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106883216A true CN106883216A (zh) | 2017-06-23 |
CN106883216B CN106883216B (zh) | 2020-03-13 |
Family
ID=59182583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710220841.7A Active CN106883216B (zh) | 2017-04-06 | 2017-04-06 | 一种奥希替尼的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106883216B (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108008034A (zh) * | 2017-11-23 | 2018-05-08 | 中山奕安泰医药科技有限公司 | 采用气相色谱法检测n,n,n’-三甲基乙二胺纯度的方法 |
CN108017620A (zh) * | 2016-10-31 | 2018-05-11 | 北京睿创康泰医药研究院有限公司 | 甲磺酸奥希替尼工艺杂质的制备方法 |
CN109134435A (zh) * | 2018-10-29 | 2019-01-04 | 湖南大学 | 一种奥希替尼azd9291的合成方法 |
CN109438422A (zh) * | 2018-12-11 | 2019-03-08 | 江南大学 | 一种奥希替尼杂质及其制备方法 |
US10513509B2 (en) | 2016-05-26 | 2019-12-24 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
CN112028880A (zh) * | 2020-11-05 | 2020-12-04 | 北京鑫开元医药科技有限公司 | 一种奥希替尼二聚体、其制备方法及其用途 |
CN112341346A (zh) * | 2020-10-30 | 2021-02-09 | 烟台舜康生物科技有限公司 | 一种奥希替尼中间体的合成方法 |
CN112645934A (zh) * | 2020-12-25 | 2021-04-13 | 中山奕安泰医药科技有限公司 | 奥斯替尼中间体及其精制方法 |
CN113956259A (zh) * | 2021-11-05 | 2022-01-21 | 华北水利水电大学 | 一种丙烯酰胺类药物的制备方法 |
CN115433169A (zh) * | 2022-11-07 | 2022-12-06 | 北京鑫开元医药科技有限公司 | 一种甲磺酸奥希替尼二聚体的制备方法 |
WO2023194531A1 (en) * | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Improved process for the manufacture of osimertinib |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103702990A (zh) * | 2011-07-27 | 2014-04-02 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 |
CN104817541A (zh) * | 2015-05-11 | 2015-08-05 | 苏州东南药业股份有限公司 | 一种抗肿瘤药物的合成方法 |
CN106117185A (zh) * | 2015-08-31 | 2016-11-16 | 广州科擎新药开发有限公司 | 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用 |
CN106543060A (zh) * | 2016-10-31 | 2017-03-29 | 湖南欧亚生物有限公司 | 一种奥斯替尼甲磺酸盐的制备方法 |
-
2017
- 2017-04-06 CN CN201710220841.7A patent/CN106883216B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103702990A (zh) * | 2011-07-27 | 2014-04-02 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 |
CN104817541A (zh) * | 2015-05-11 | 2015-08-05 | 苏州东南药业股份有限公司 | 一种抗肿瘤药物的合成方法 |
CN106117185A (zh) * | 2015-08-31 | 2016-11-16 | 广州科擎新药开发有限公司 | 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用 |
CN106543060A (zh) * | 2016-10-31 | 2017-03-29 | 湖南欧亚生物有限公司 | 一种奥斯替尼甲磺酸盐的制备方法 |
Non-Patent Citations (1)
Title |
---|
高磊 等: "奥希替尼合成路线图解", 《广东化工》 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11098030B2 (en) | 2016-05-26 | 2021-08-24 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
US10513509B2 (en) | 2016-05-26 | 2019-12-24 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
CN108017620A (zh) * | 2016-10-31 | 2018-05-11 | 北京睿创康泰医药研究院有限公司 | 甲磺酸奥希替尼工艺杂质的制备方法 |
CN108008034A (zh) * | 2017-11-23 | 2018-05-08 | 中山奕安泰医药科技有限公司 | 采用气相色谱法检测n,n,n’-三甲基乙二胺纯度的方法 |
CN109134435A (zh) * | 2018-10-29 | 2019-01-04 | 湖南大学 | 一种奥希替尼azd9291的合成方法 |
CN109134435B (zh) * | 2018-10-29 | 2023-01-03 | 湖南大学 | 一种奥希替尼azd9291的合成方法 |
CN109438422A (zh) * | 2018-12-11 | 2019-03-08 | 江南大学 | 一种奥希替尼杂质及其制备方法 |
CN112341346A (zh) * | 2020-10-30 | 2021-02-09 | 烟台舜康生物科技有限公司 | 一种奥希替尼中间体的合成方法 |
CN112341346B (zh) * | 2020-10-30 | 2024-03-08 | 烟台舜康生物科技有限公司 | 一种奥希替尼中间体的合成方法 |
CN112028880A (zh) * | 2020-11-05 | 2020-12-04 | 北京鑫开元医药科技有限公司 | 一种奥希替尼二聚体、其制备方法及其用途 |
CN112645934A (zh) * | 2020-12-25 | 2021-04-13 | 中山奕安泰医药科技有限公司 | 奥斯替尼中间体及其精制方法 |
CN113956259A (zh) * | 2021-11-05 | 2022-01-21 | 华北水利水电大学 | 一种丙烯酰胺类药物的制备方法 |
WO2023194531A1 (en) * | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Improved process for the manufacture of osimertinib |
CN115433169A (zh) * | 2022-11-07 | 2022-12-06 | 北京鑫开元医药科技有限公司 | 一种甲磺酸奥希替尼二聚体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106883216B (zh) | 2020-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106883216A (zh) | 一种奥希替尼的制备方法 | |
CN104817541B (zh) | 一种抗肿瘤药物的合成方法 | |
CN106366022B (zh) | 一种用于制备azd9291的中间体及其制备方法和应用 | |
CN105566215B (zh) | 一种瑞戈非尼的制备方法 | |
CN103880762B (zh) | 一种1,2,3-三氮唑类化合物的制备方法 | |
CN108864050A (zh) | 一种合成安罗替尼及其盐酸盐的方法 | |
CN103601645B (zh) | 1-(苯乙基氨基)丙烷-2-醇类化合物或其盐的制备方法 | |
CN107698523A (zh) | 一种酪氨酸激酶抑制剂吉非替尼的制备方法 | |
CN108503597B (zh) | 一种吉非替尼的高效制备方法 | |
CN102675201B (zh) | 一种由邻硝基酚制备2-甲基-8-氨基喹啉的方法 | |
EP4045494A1 (en) | Synthesis of 6-methyl-n1-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine | |
CN108164423B (zh) | 一种盐酸萘替芬的制备方法 | |
CN109988108B (zh) | 一种卡博替尼的制备方法 | |
Yin et al. | Assembly of N, N-disubstituted-N′-arylureas via a copper-catalyzed one-pot three-component reaction of aryl bromides, potassium cyanate, and secondary amines | |
CN105820124B (zh) | 一种比尼替尼的合成方法 | |
CN106083631B (zh) | 一种对氨基苯乙酸的制备方法 | |
CN106749038A (zh) | 一种氟班色林的制备方法 | |
CN104003887A (zh) | 一种盐酸溴己新的制备方法 | |
CN104829514B (zh) | 一种药物中间体的合成方法 | |
CN105111089B (zh) | 吡沙洛姆中间体 | |
CN104583204A (zh) | 用于合成取代的γ内酰胺的方法 | |
CN103524408A (zh) | 一种利用相转移催化反应制备7-氯喹哪啶的方法 | |
CN108863900A (zh) | 一种5-氟吲哚-2-酮的制备方法 | |
CN110590641B (zh) | 一种3-羟基异吲哚-1-酮系列化合物的绿色制备方法 | |
CN103848773B (zh) | 一种制备双吲哚基芴衍生物的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20181211 Address after: 215634 No. 2 Nanjing Middle Road, Yangtze River Chemical Industrial Park, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province Applicant after: ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. Address before: 215634 Building D, No. 7 Guangdong Road, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province (Weisheng) Applicant before: ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. Applicant before: WUYANG WEISEN BIOMEDICAL CO.,LTD. |
|
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of oxitinib Effective date of registration: 20210930 Granted publication date: 20200313 Pledgee: Agricultural Bank of China Limited Zhangjiagang branch Pledgor: ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. Registration number: Y2021320010400 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 215634 No. 2 Nanjing Middle Road, Yangtze River Chemical Industrial Park, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province Patentee after: Weisheng Biomedical (Suzhou) Co.,Ltd. Address before: 215634 No. 2 Nanjing Middle Road, Yangtze River Chemical Industrial Park, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province Patentee before: ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 2, Nanjing Middle Road, Jiangsu Yangzijiang Chemical Industrial Park, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province, 215634 Patentee after: Wison Biomedical (Suzhou) Co.,Ltd. Address before: 215634 No. 2 Nanjing Middle Road, Yangtze River Chemical Industrial Park, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province Patentee before: Weisheng Biomedical (Suzhou) Co.,Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221031 Granted publication date: 20200313 Pledgee: Agricultural Bank of China Limited Zhangjiagang branch Pledgor: ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. Registration number: Y2021320010400 |